Sentiment Summary
Recent Events
Eli Lilly's Q2 2026 quarterly earnings release, estimated as high importance due to being a primary volatility driver with a likely >=10% price impact, is scheduled.
Q2 2026 earnings release and conference call on July 29, 2026, scheduled.
Ex-dividend date for the final dividend of HK$0.25 per share on 2026-07-20 scheduled, with payment on 2026-08-04; low importance as dividend adjustments typically result in <5% price impact.
Annual General Meeting (AGM) on June 16, 2026, to approve the annual report and dividend payout for the fiscal year; medium importance as a standard corporate governance event confirming shareholder returns, scheduled.
Medtronic is scheduled to report financial results for its fourth quarter and full fiscal year 2026 on June 3, 2026. This is a future event, so importance is an estimate based on the typical high impact of full-year earnings reports, scheduled
Ex-dividend date on June 3, 2026 for a proposed final dividend of RMB 0.5390 and a special dividend of RMB 0.6714 (AGM: May 28, Record Date: June 8); ≥5% price impact scheduled.
Quarterly dividend of $1.34 per share to go ex-dividend on May 26, 2026. The 3.1% increase was announced on April 14, 2026, scheduled.
Publication of Full-Year Results for the 2025/26 fiscal year on May 18, 2026, to detail performance and provide an outlook; high importance as annual results are key financial disclosures with potential for significant market reaction, expected.
The final dividend for FY2025 of RMB 15.7927 per 10 shares will trade ex-dividend on May 13, 2026. Low importance is estimated as the ex-dividend price adjustment is typically around 1-2%, scheduled.
On 2026-05-12, announced a global strategic collaboration and license agreement with Bristol-Myers Squibb (BMY) covering 13 early-stage programs in oncology, hematology, and immunology with potential milestones of $15.2 billion; this massive deal is estimated to have a >10% price impact.
The company's actual controllers, Chairman Ye Xiaoping and Director Cao Xiaochun, were placed under investigation by the CSRC on May 12, 2026, for suspected information disclosure violations, which is estimated to have a price impact of over 10% due to management risk; expected.
SenseTime's subsidiary, SenseGo, launched the 'SenseMartGo' robotic convenience store solution on May 12, 2026, which has been deployed in several locations in Shanghai.
XtalPi, in collaboration with a subsidiary of CK Life Sciences, announced positive preclinical results for its AI-driven cancer vaccine platform at the AACR Annual Meeting; low importance is estimated as preclinical data is early-stage scheduled.
Law firm Bronstein, Gewirtz & Grossman, LLC announced on May 12, 2026, it is investigating potential claims concerning corporate wrongdoing; estimated price impact is >1%.
Exclusive strategic collaboration with GSK to commercialize bepirovirsen in mainland China on 2026-05-11; high impact expected from first-in-class therapy market potential, scheduled
On May 11, 2026, CeriBell reported Q1 2026 financial results, posting revenue of $26.5 million (+29% YoY), which beat estimates. However, the loss per share of $0.52 missed consensus estimates. The company raised its full-year 2026 revenue guidance to $112-$116 million.
Subsidiary Henlius received US FDA approval to conduct a Phase I clinical trial for HLX05-N, a biosimilar of Cetuximab Injection, for metastatic colorectal cancer; 1-2% price impact estimated due to early-stage clinical progress expected.
Announced on 2026-05-10 that China's NMPA granted a third Breakthrough Therapy Designation (BTD) for IBI363; Medium importance estimated due to expedited regulatory path.
Subsidiary Henlius received European Commission approval for two new indications for its anti-PD-1 mAb Serplulimab (Hetronifly®) in esophageal and lung cancers; 5-7% price impact estimated due to market expansion expected.
The company's self-developed B7-H3 targeted antibody-drug conjugate (ADC), HS-20093, was granted Breakthrough Therapy Designation by China's NMPA for treating esophageal squamous cell carcinoma on May 9, 2026, with the announcement made on May 11, 2026.
Announced on 2026-05-08 that China's NMPA approved the Mazdutide pre-filled multi-dose pen; Medium importance estimated due to enhanced product convenience.
The supplemental New Drug Application (sNDA) for Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab for 1L PD-L1+ NSCLC was accepted by China's NMPA on May 8, 2026. This key pipeline progress is estimated to have a ≥5% price impact expected.
Medtronic's stock price reached a new 52-week low of approximately $77.15 on May 8, 2026, reflecting a year-to-date decline of over 18%.
On 2026-05-08, announced clinical trial approval notices from China's NMPA for five drugs, including HRS-6093 tablets and Injectable SHR-1826; these regulatory approvals are estimated to have a >1% price impact.
On 2026-05-07, reported Q1 2026 revenue of $759.9 million and non-GAAP EPS of $1.12, beating analyst estimates and raising full-year guidance; high importance (≥10%) estimated due to significant earnings beat and outlook raise, expected.
On 2026-05-07, announced the receipt of two FDA 510(k) clearances for its Scripps patient-specific lumbar spacers and rods, making it the only company with a fully integrated patient-specific lumbar implant portfolio; medium importance (≥5%) estimated as it strengthens the product portfolio, expected.
Major venture capital backer, Bessemer Venture Partners, and other insiders reported significant stock sales on May 7-8 under pre-arranged trading plans following a post-earnings price surge. Low importance as pre-arranged sales usually have ≥1% but limited impact.
The FDA's proposed rule to prohibit compounding pharmacies from creating copycat GLP-1 drugs, likely providing market protection with a >=1% price impact, is expected.